Search

Displaying results 2941 - 2950 of 4301 in total
  1. Drug

    Ethanolamine oleate

    go.drugbank.com/drugs/DB06689
    Approved

    Ethanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.

  2. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent. Unlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FD...

  3. Drug

    Benzimate

    go.drugbank.com/drugs/DB05170
    Experimental

    It is currently under investigation by AmpliMed and is in phase I of clinical trial. … The anti-cancer and anti-viral activity of the benzimidazoles was originally investigated by the Proctor & Gamble Company beginning in the 1990's.

  4. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.

  5. Drug

    Procaine benzylpenicillin

    go.drugbank.com/drugs/DB09320
    ApprovedVet approved

    Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin.

  6. Drug

    Celiprolol

    go.drugbank.com/drugs/DB04846
    ApprovedInvestigationalWithdrawn

    Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.

  7. Drug

    Bavituximab

    go.drugbank.com/drugs/DB05136
    Investigational

    It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.

  8. Drug

    OSI-7904L

    go.drugbank.com/drugs/DB05457
    Investigational

    Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.

  9. Drug

    Atracurium besylate

    go.drugbank.com/drugs/DB00732
    Approved

    A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate no...

  10. Drug

    MUC1 Dendritic Cell Vaccine

    go.drugbank.com/drugs/DB05477
    Investigational

    Dendritic cells not only activate lymphocytes to induce the immune response, but they also minimize autoimmune reactions by downplaying self-antigens to stimulated T-cells.